Gene amplification of ZNF217 located at chr20q13.2 is associated with lymph node metastasis in ovarian clear cell carcinoma

Anticancer Research

Volumn 32, Issue 8, 2012, Pages 3091-3095

  Rahman, Mohammed Tanjimur ^a   Nakayama, Kentaro ^a   Rahman, Munmun ^a   Katagiri, Hiroshi ^a   Katagiri, Atsuko ^a   Ishibashi, Tomoka ^a   Ishikawa, Masako ^a   Iida, Kouji ^a   Nakayama, Naomi ^a   Otsuki, Yoshiro ^b   Nakayama, Satoru ^b   Miyazaki, Kohji ^a  

^a SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

^b SEIREI HAMAMATSU GENERAL HOSPITAL   (Japan)

Author keywords

Lymph node metastasis; Ovarian clear cell carcinoma; ZNF217 gene amplification

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; IRINOTECAN; PACLITAXEL; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN; ZINC FINGER PROTEIN 217;

AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CELL INVASION; CELL MIGRATION; CHROMOSOME 20Q13.2; CHROMOSOME ABERRATION; CLEAR CELL CARCINOMA; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE INACTIVATION; GENE SILENCING; GENETIC ANALYSIS; GENETIC ASSOCIATION; GROWTH INHIBITION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVARIAN CLEAR CELL CARCINOMA; OVARY CARCINOMA; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; WESTERN BLOTTING;

CHROMOSOMES, HUMAN, PAIR 20; FEMALE; GENE AMPLIFICATION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHATIC METASTASIS; OVARIAN NEOPLASMS; RNA, SMALL INTERFERING; TRANS-ACTIVATORS;

EID: 84865692758     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Gilks CB: Molecular abnormalities in ovarian cancer subtypes other than high-grade serous carcinoma. J Oncol 2010: 740968, 2010.
3. Cho KR and Shih Ie M: Ovarian cancer. Annu Rev Pathol 4: 287-313, 2009.
4. Kobel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C, Leung S, Bowen NJ, Ionescu DN, Rajput A, Prentice LM, Miller D, Santos J, Swenerton K, Gilks CB and Huntsman D: Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 5: e232, 2008.
5. Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T, Suzuki M, Sato I and Taguchi K: Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 88: 2584-2589, 2000.
6. Kennedy AW, Biscotti CV, Hart WR and Webster KD: Ovarian clear cell adenocarcinoma. Gynecol Oncol 32: 342-349, 1989.
7. Kobel M, Xu H, Bourne PA, Spaulding BO, Shih Ie M, Mao TL, Soslow RA, Ewanowich CA, Kalloger SE, Mehl E, Lee CH, Huntsman D and Gilks CB: IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype. Mod Pathol 22: 469-475, 2009.
8. Katagiri A, Nakayama K, Rahman MT, Rahman M, Katagiri H, Nakayama N, Ishikawa M, Ishibashi T, Iida K, Kobayashi H, Otsuki Y, Nakayama S and Miyazaki K: Loss of ARID1A expression is related to shorter progression-free survival and chemoresistance in ovarian clear cell carcinoma. Mod Pathol 25: 282-288, 2012.
9. Kuo KT, Mao TL, Jones S, Veras E, Ayhan A, Wang TL, Glas R, Slamon D, Velculescu VE, Kuman RJ and Shih Ie M: Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol 174: 1597-1601, 2009.
10. Rahman MT, Nakayama K, Rahman M, Nakayama N, Ishikawa M, Katagiri A, Iida K, Nakayama S, Otsuki Y, Shih IM and Miyazaki K: Prognostic and therapeutic impact of the chromosome 20q13.2 ZNF217 locus amplification in ovarian clear cell carcinoma. Cancer doi: 10.1002/cncr.26598, 2011.
11. Nakayama K, Nakayama N, Jinawath N, Salani R, Kurman RJ, Shih Ie M and Wang TL: Amplicon profiles in ovarian serous carcinomas. Int J Cancer 120: 2613-2617, 2007.
12. Sun G, Zhou J, Yin A, Ding Y and Zhong M: Silencing of ZNF217 gene influences the biological behavior of a human ovarian cancer cell line. Int J Oncol 32: 1065-1071, 2008.
13. Iuchi S: Three classes of C2H2 zinc finger proteins. Cell Mol Life Sci 58: 625-635, 2001.
14. You A, Tong JK, Grozinger CM and Schreiber SL: CoREST is an integral component of the CoREST- human histone deacetylase complex. Proc Natl Acad Sci USA 98: 1454-1458, 2001.
15. Hakimi MA, Dong Y, Lane WS, Speicher DW and Shiekhattar R: A candidate X-linked mental retardation gene is a component of a new family of histone deacetylase-containing complexes. J Biol Chem 278: 7234-7239, 2003.
16. Lee MG, Wynder C, Cooch N and Shiekhattar R: An essential role for CoREST in nucleosomal histone 3 lysine 4 demethylation. Nature 437: 432-435, 2005.
17. Shi Y, Sawada J, Sui G, Affar el B, Whetstine JR, Lan F, Ogawa H, Luke MP, Nakatani Y and Shi Y: Coordinated histone modifications mediated by a CtBP co-repressor complex. Nature 422: 735-738, 2003.
18. Chinnadurai G: CtBP, an unconventional transcriptional corepressor in development and oncogenesis. Mol Cell 9: 213-224, 2002.
19. Cowger JJ, Zhao Q, Isovic M and Torchia J: Biochemical characterization of the zinc-finger protein 217 transcriptional repressor complex: identification of a ZNF217 consensus recognition sequence. Oncogene 26: 3378-3386, 2007.
20. Weinstein IB and Joe A: Oncogene addiction. Cancer Res 68: 3077-3080, 2008.
21. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182, 1987.
22. Pauletti G, Dandekar S, Rong H, Ramos L, Peng H, Seshadri R and Slamon DJ: Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 18: 3651-3664, 2000.